Back

Physicians’ Education Resource

  • Carcinoma, Non-Small-Cell Lung
  • Immunoconjugates

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Welcome to this OncoByte Adaptive Learning Pathway! Each OncoByte video features a 5-minute presentation by our expert faculty on a key foundational topic related to the use of TROP2-targeting antibody-drug conjugates (ADCs) in the treatment of non-small cell lung cancer (NSCLC). Prior to watching an OncoByte, you will be asked a question on the topic to assess your baseline knowledge and confidence. If you answer the question correctly and confidently, you will continue to the next topic. If you answer the question incorrectly or without high confidence, you will continue to the OncoByte video. After proceeding through your customized learning pathway, you will be led to panel discussions. Our expert faculty will help you synthesize the latest information and data on the safety and efficacy of TROP2-targeting ADCs in patients with NSCLC.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • Credit · Up to 1.5 credits
  • Commercial Support
  • Released
    Jul 31, 2026
  • Last day to claim credit
    Aug 1, 2027 10 months left